全文获取类型
收费全文 | 1741篇 |
免费 | 96篇 |
国内免费 | 78篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 74篇 |
妇产科学 | 28篇 |
基础医学 | 173篇 |
口腔科学 | 32篇 |
临床医学 | 251篇 |
内科学 | 340篇 |
皮肤病学 | 106篇 |
神经病学 | 58篇 |
特种医学 | 267篇 |
外科学 | 101篇 |
综合类 | 49篇 |
预防医学 | 103篇 |
眼科学 | 36篇 |
药学 | 125篇 |
中国医学 | 3篇 |
肿瘤学 | 129篇 |
出版年
2019年 | 13篇 |
2018年 | 16篇 |
2017年 | 12篇 |
2016年 | 19篇 |
2015年 | 20篇 |
2014年 | 24篇 |
2013年 | 30篇 |
2012年 | 41篇 |
2011年 | 44篇 |
2010年 | 53篇 |
2009年 | 57篇 |
2008年 | 39篇 |
2007年 | 72篇 |
2006年 | 44篇 |
2005年 | 52篇 |
2004年 | 30篇 |
2003年 | 25篇 |
2002年 | 33篇 |
2001年 | 37篇 |
2000年 | 51篇 |
1999年 | 31篇 |
1998年 | 90篇 |
1997年 | 74篇 |
1996年 | 66篇 |
1995年 | 54篇 |
1994年 | 48篇 |
1993年 | 47篇 |
1992年 | 56篇 |
1991年 | 55篇 |
1990年 | 46篇 |
1989年 | 57篇 |
1988年 | 47篇 |
1987年 | 45篇 |
1986年 | 34篇 |
1985年 | 43篇 |
1984年 | 39篇 |
1983年 | 27篇 |
1982年 | 24篇 |
1981年 | 23篇 |
1980年 | 17篇 |
1979年 | 21篇 |
1978年 | 17篇 |
1977年 | 26篇 |
1976年 | 28篇 |
1975年 | 27篇 |
1974年 | 19篇 |
1973年 | 17篇 |
1972年 | 14篇 |
1971年 | 17篇 |
1970年 | 20篇 |
排序方式: 共有1915条查询结果,搜索用时 15 毫秒
1.
P Avalos-Peralta† A Herrera† JJ Ríos-Martín‡ AM Pérez-Bernal† D Moreno-Ramírez† F Camacho† 《Journal of the European Academy of Dermatology and Venereology》2006,20(1):79-83
We report the case of a patient with a 13-year history of pemphigus vulgaris (PV) treated with immunosuppressive agents, prednisone and mycophenolate mofetil who had developed lesions of Kaposi's sarcoma (KS) on a sole plaque of PV that had been previously treated with intralesional injections of steroids. The lesions were surgically removed and polymerase chain reaction (PCR) demonstrated human herpesvirus-8 (HHV-8) DNA. There were neither recurrences nor later dissemination of KS following gradual decrease of the immunosuppressive therapy. We suggest that the treatment with intralesional steroids may have influenced the local reactivation of a latent infection of the virus, determining the appearance of this localized KS. 相似文献
2.
Jaime Guevara-Aguirre Arlan L Rosenbloom Marco Guevara-Aguirre Kemal Yariz Jeanette Saavedra Lisa Baumbach Jonathan Shuster 《Growth hormone & IGF research》2007,17(3):261-264
CONTEXT & OBJECTIVE: The Ecuadorian GH receptor deficiency (GHRD)/Laron syndrome population is the only large cohort with a single GHR mutation (E180 splice), permitting identification of numerous carrier and noncarrier first-degree relatives, to ascertain effects of heterozygosity on GH-dependent IGF-I and IGFBP-3 concentrations and on growth. DESIGN: First-degree relatives (n=212) of GHRD patients had specimens taken for IGF-I, IGFBP-3, and GHR genotyping. Normal statured (n=40) and short statured (n=40) unrelated controls had measurement of IGF-I, IGFBP-3, and stature. RESULTS: There were no significant differences between heterozygous and homozygous normal relatives in IGF-I or IGFBP-3 standard deviation scores (SDS). Heterozygous relatives had lower mean height SDS than did homozygous normals, but with extensive overlap between genotype groups in both child and adult relatives. Height SDS in general did not relate to IGF-I or IGFBP-3 concentrations. CONCLUSIONS: GH-dependent IGF-I and IGFBP-3 secretion is not affected by heterozygosity for the E180 splice mutation that causes GHRD/Laron syndrome in the Ecuadorian population. Heterozygosity is associated with reduction in mean statural SDS, but this is not sufficient to be clinically important and not mediated through measurable differences in circulating IGF-I or IGFBP-3 related to genotype. 相似文献
3.
CM Reid M. Nelson P. Beckinsale P. Ryan LMH Wing LJ Beilin MA Brown GLR Jennings CI Johnston J. Marley JJ McNeil TO Morgan J. Shaw ID Steven MJ West 《Clinical and experimental pharmacology & physiology》1997,24(5):370-373
1. The present study aimed to determine the feasibility of conducting a 5 year cardiovascular outcome trial of the treatment of 6000 elderly hypertensive patients in Australian general practices. 2. General practitioners (GPs) were invited to participate by mail and personal follow-up. Patient records were reviewed to identify subjects for a blood pressure (BP) screening programme. Blood pressure was measured on three occasions and eligible subjects were included if the average BP was 160 mmHg systolic or 90 mmHg diastolic if systolic BP was 140 mmHg. 3. Seven hundred and forty-one GPs were approached and 89 were enrolled in the study (12% of mail invites and 75% of those receiving a personal contact). In 16 practices where screening was completed, 82 000 records were reviewed to identify 4% patients eligible for screening. Twenty-two per cent of eligible subjects attended screening. Of 1938 subjects screened, 180 (9%) had BP 5=160/90 mmHg. Forty-seven percent of subjects (n = 916) were receiving antihypertensive therapy and 184 (20%) were withdrawn from therapy. One hundred and sixteen (63%) of these subjects had BP return to study entry levels within 6 weeks. Fifty-seven newly diagnosed and 81 previously treated subjects were randomized (7% of the screened population). 4. Based on the high participation rate of GPs, the response rate of patients to attend a BP screening programme and the 7% randomization to screening ratio for entry into the study, the ANBP2 pilot study has demonstrated that it is feasible to recruit subjects from Australian general practices to a cardiovascular outcome trial. 相似文献
4.
5.
6.
E Shuster 《Human reproduction (Oxford, England)》1991,6(8):1176-1180
Non-genetic surrogacy characterizes a situation where the gestational mother is not the genetic mother. It further widens a circle that started with the introduction of in-vitro fertilization (IVF) and creates problems in defining motherhood and identifying at birth the mother who will have the rights and responsibilities of rearing the child. 相似文献
7.
V V Joshi A B Cantor G Altshuler E W Larkin J S Neill J J Shuster C T Holbrook F A Hayes R Nitschke M H Duncan 《Cancer》1992,69(8):2197-2211
Histologic sections (minimum of four sections per patient) from 211 patients with neuroblastoma were reviewed. The tumors were resected before therapy, which was standardized according to age and stage. Low mitotic rate (MR) (less than or equal to ten per ten high-power fields) and calcification emerged as the most significant prognostic features after statistical analysis by stepwise log-rank tests (P less than 0.0001 and P = 0.0065, respectively). Histologic Grades 1, 2, and 3 were defined on the basis of the presence of both, any one, or none of these two prognostic features, respectively (Grade 3 had absence of low MR, i.e., these tumors had high MR [greater than ten per ten high-power fields]). Statistically significant differences in survival were observed in the grades after adjusting for age and stage (P less than 0.001). The degree of differentiation, although significant by itself, was no longer significant after adjusting for the grades. Age groups (less than or equal to 1 versus greater than 1 year of age), which also emerged as an independent prognostic feature (P less than 0.001), were linked with the grades to define two risk groups as follows: (1) a low-risk (LR) group consisting of patients in both age groups with Grade 1 tumors and patients 1 year of age or younger with Grade 2 tumors and (2) a high-risk (HR) group consisting of patients older than 1 year of age with Grade 2 tumors and patients in both age groups with Grade 3 tumors. The difference in survival between LR (160 cases) and HR groups (51 cases) was statistically significant (P less than 0.001). Concordance between these LR and HR groups and the Shimada classification was observed in 84% of cases. The new histologic grading system has the following advantages: (1) use of familiar terminology and histologic features in the grading system and (2) relative ease of assessment because the degree of differentiation does not need to be determined. The grading system should be tested on a new data set with an appropriate histologic sample of similar size to confirm these results. 相似文献
8.
Michael L. Graham Jonathan J. Shuster Barton A. Kamen David L. Cheo Matthew P. Harrison Brigid G. Leventhal D. Jeanette Pullen V. Michael Whitehead 《Cancer chemotherapy and pharmacology》1992,31(3):217-222
Summary We enrolled children with acute lymphoblastic leukemia (ALL) in a Pediatric Oncology Group (POG) pilot study to monitor erythrocyte (RBC) methotrexate (MTX) and folate (F) levels before and during treatment. The mean value for RBCF at diagnosis was 0.86±0.46 nmol/ml RBC in the 214 patients who achieved remission and 1.21±0.74 nmol/ml RBC in the 10 patients who did not (P=0.020). Folate levels tended to increase during remission induction, but they dropped following an intensive consolidation with methotrexate to levels that were sustained throughout chemotherapy treatment. Methotrexate levels reached mean values of approximately 0.15 nmol/ml RBC at the end of an intensive methotrexate consolidation, then fell to levels that were sustained throughout maintenance therapy. There was a weak correlation between improved event-free survival and higher RBCMTX levels after consolidation, but no correlation was found between improved survival and the level of RBCMTX or RBCF during maintenance therapy. A larger study with more complete data is needed to determine whether RBCMTX or RBCF might be useful in predicting event-free survival in patients with ALL.This work was supported in part by grants from the National Cancer Institute and the National Institute of Health (CA-30969, CA-28476, CA29139, CA-159-89, and CA-33587) 相似文献
9.
10.
SUMMARY A young patient presenting with splenomegaly and hypersplenism was inadvertently found to have selective IgA deficiency. There were no symptoms of immunodeficiency and the patient responded well to splenectomy, with return of blood counts to normal without adverse effects. No other cause for the hypersplenism was found. We postulate selective IgA deficiency as a cause of splenomegaly and hypersplenism. 相似文献